Last reviewed · How we verify
Vildagliptin (LAF237)
Vildagliptin (LAF237) is a DPP-4 inhibitor Small molecule drug developed by Novartis. It is currently FDA-approved for Type 2 diabetes mellitus as monotherapy or in combination with other antidiabetic agents. Also known as: Vildagliptin.
Vildagliptin inhibits dipeptidyl peptidase-4 (DPP-4), prolonging the activity of incretin hormones to increase insulin secretion and reduce glucagon in response to meals.
Vildagliptin, also known as LAF237, is a small molecule dipeptidyl peptidase 4 inhibitor. It has been studied in clinical trials for conditions such as type 2 diabetes mellitus and chronic foot ulcers.
At a glance
| Generic name | Vildagliptin (LAF237) |
|---|---|
| Also known as | Vildagliptin |
| Sponsor | Novartis |
| Drug class | DPP-4 inhibitor |
| Target | DPP-4 (dipeptidyl peptidase-4) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
By blocking DPP-4, vildagliptin prevents the degradation of GLP-1 and GIP, endogenous incretin hormones that stimulate glucose-dependent insulin secretion and suppress glucagon secretion. This mechanism lowers postprandial and fasting blood glucose levels in patients with type 2 diabetes without causing hypoglycemia when used as monotherapy, since insulin secretion is glucose-dependent.
Approved indications
- Type 2 diabetes mellitus as monotherapy or in combination with other antidiabetic agents
Common side effects
- Headache
- Nasopharyngitis
- Dizziness
- Hypoglycemia (when combined with insulin or sulfonylureas)
Key clinical trials
- A Prospective, Multicenter, Randomized, Open-label Study of 12 Week Duration to Evaluate the Effect of VILDagliptin Added to Insulin on Glycaemic Control in haemoDIALyzed Patients With Type 2 Diabetes: Probe Analysis of CGM (PHASE4)
- Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. (PHASE4)
- Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary Syndrome (PHASE2, PHASE3)
- Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients (PHASE2)
- Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk Factors (PHASE4)
- Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia (PHASE2)
- The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder Patients (PHASE1, PHASE2)
- A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vildagliptin (LAF237) CI brief — competitive landscape report
- Vildagliptin (LAF237) updates RSS · CI watch RSS
- Novartis portfolio CI
Frequently asked questions about Vildagliptin (LAF237)
What is Vildagliptin (LAF237)?
How does Vildagliptin (LAF237) work?
What is Vildagliptin (LAF237) used for?
Who makes Vildagliptin (LAF237)?
Is Vildagliptin (LAF237) also known as anything else?
What drug class is Vildagliptin (LAF237) in?
What development phase is Vildagliptin (LAF237) in?
What are the side effects of Vildagliptin (LAF237)?
What does Vildagliptin (LAF237) target?
Related
- Drug class: All DPP-4 inhibitor drugs
- Target: All drugs targeting DPP-4 (dipeptidyl peptidase-4)
- Manufacturer: Novartis — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus as monotherapy or in combination with other antidiabetic agents
- Also known as: Vildagliptin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing